From clinical trial to clinical experience: Lecanemab therapy in a real-world case series [0.03%]
从临床试验到临床实践——仑卡奈单抗治疗真实世界病例系列分析
Michael Sonson,Golnaz Yadollahikales,Allison Flores et al.
Michael Sonson et al.
The approval of anti-amyloid therapies has expanded therapeutic options for patients with Alzheimer's disease (AD), but the pivotal trials that proved their efficacy restrict their applicability to a selected patient population. We describe...
Associations of plasma p-Tau217 with cognitive domain performance in clinically unimpaired participants: Evidence from HABS-HD [0.03%]
血浆p-Tau217与临床无症状参与者的认知域表现的相关性：HABS-HD研究的证据
Zara Najmi,Anhiti Dharmapuri,Joey A Contreras et al.
Zara Najmi et al.
Introduction: The relationship between plasma phosphorylated tau 217 (p-Tau217) and domain-specific cognitive performance across race and ethnic groups remains unclear. ...
Evaluation of fully automated ApoE4 proteotyping for APOE ε4 genotype estimation in the FINDERI cohort [0.03%]
全自动ApoE4蛋白质分型评估FINDER I队列中APOE ε4基因型的方法
Hans-Wolfgang Klafki,Carlotta Derad,Maike Hoberg et al.
Hans-Wolfgang Klafki et al.
Introduction: Carriers of the ε4 allele of the apolipoprotein E (APOE) gene have an increased risk for Alzheimer's disease (AD) and amyloid-related imaging abnormalities (ARIAs) upon anti-amyloid beta (Αβ) immunotherap...
Design and baseline findings of the NEODEM prospective cohort on early-onset neurodegenerative dementia [0.03%]
NEODEM前瞻性队列研究的设计与基线结果:关于早发性神经退行性痴呆
Sophie Auriacombe,Emmanuelle Durand,Marion Kret et al.
Sophie Auriacombe et al.
Introduction: Functional prognosis of early-onset neurodegenerative dementia (EOD) remains poorly understood. Methods: The Neurodegener...
White matter hyperintensities in Alzheimer's disease in the era of anti-amyloid therapies [0.03%]
抗淀粉样蛋白疗法时代阿尔茨海默病的白质高信号
Antoine Garnier-Crussard,Mahsa Dadar,Nicolas Villain et al.
Antoine Garnier-Crussard et al.
White matter hyperintensities (WMHs) are highly prevalent in Alzheimer's disease (AD) and arise from interacting vascular pathologies (including hypertensive small vessel disease and cerebral amyloid angiopathy) alongside inflammatory and n...
Interchangeability of CSF and PET to identify Alzheimer's disease pathology [0.03%]
脑脊液与PET在识别阿尔茨海默病病理改变中的互换性
Samantha C Burnham,Anupa K Arora,Leonardo Iaccarino et al.
Samantha C Burnham et al.
Introduction: Establishing interchangeability between cerebrospinal fluid (CSF) and positron emission tomography (PET) for patient identification may improve access to Alzheimer's disease (AD) therapies. ...
Identification of cognitive impairment using the Lancet Commission's risk factors and Medicare administrative data [0.03%]
基于 lancet 委员会危险因素和 medicare 行政数据识别认知障碍
Hankyung Jun,Wei Ye,Ying Liu et al.
Hankyung Jun et al.
Introduction: Prediction models based on administrative data may present a scalable opportunity to identify risk of cognitive impairment, but their accuracy relative to models using richer information is uncertain. ...
Development of a Japanese version of the Family Stigma Instrument for dementia [0.03%]
痴呆的家庭耻辱量表的日语版的开发
Taiji Noguchi,Jem Bhatt,Ayane Komatsu et al.
Taiji Noguchi et al.
Introduction: Overcoming dementia-related stigma is a global challenge, but tools to assess stigma among family caregivers of people living with dementia remain limited. This study examined the validity and reliability of...
Reliability of remote self-administered Web-based digital cognitive measures and comparison to in-person neuropsychological tests: Stricker Learning Span, Symbols Test, and the Mayo Test Drive Screening Battery Composite [0.03%]
基于网络的认知测量的可靠性及其与当面进行的心理测试的比较：Stricker学习跨度测验、符号测验以及梅奥筛查量表综合分析
Morgan A Hughes,Ryan D Frank,Rita L Taylor et al.
Morgan A Hughes et al.
Introduction: We describe the reliability of remote self-administered digital cognitive measures completed via the Mayo Test Drive (MTD) web-based platform. ...
Novel insights into early Alzheimer's disease: quantitative gradient recalled echo MRI reveals preatrophic neuronal and myelin injury concurrent with emerging amyloid pathology [0.03%]
阿尔茨海默病新见解——定量梯度回波磁共振揭示淀粉样蛋白病理改变早期阶段的同时发生的神经元和髓鞘损伤
Satya V V N Kothapalli,Tammie L S Benzinger,Randall J Bateman et al.
Satya V V N Kothapalli et al.
Background: Brain amyloid accumulation is considered an early sign of Alzheimer's disease (AD) pathology, appearing decades before manifestation of clinical symptoms. However, very little is known about neurodegeneration ...